Small caps round-up: Transense Tech, Hightex, Verona Pharma
Transense Technologies, which provides sensor systems for the transportation and industrial markets, has reported that its trading division, Translogik, has received an initial order for its iTrack Tyre Temperature and Pressure Monitoring Systems for mining and off-the-road vehicles from its Indonesian distributor, AutoRFID Solutions.
Transense Technologies, which provides sensor systems for the transportation and industrial markets, has reported that its trading division, Translogik, has received an initial order for its iTrack Tyre Temperature and Pressure Monitoring Systems for mining and off-the-road vehicles from its Indonesian distributor, AutoRFID Solutions.
The system will be installed as part of a pilot scheme on three of the 168 vehicles at the ADARO mine in Indonesia, one of AutoRFID's clients. Graham Storey, Chief Executive Officer of Transense, said it is "very encouraging that our success in South Africa has triggered this order in what is a new territory for us".
Hightex Group, a systems engineering company, has been selected, along with its Brazilian construction partner SEPA, to engineer and install the membrane structure of the roof of the Beira-Rio Stadium in Porto Alegre, a 2014 FIFA World Cup venue. The deal, which has a value in the region of €10m, marks the firm's second contract win in Brazil. The stadium is the fifth largest in Brazil, and will accommodate around 50,000 spectators. Work will begin immediately and is due to be completed in 2013.
MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Verona Pharma, a drug discovery company, has been granted a new patent for its lead drug candidate, RPL554, in the US. The product is being developed for the treatment of patients with chronic respiratory diseases such as chronic obstructive pulmonary disease (COPD) and asthma. The company is currently carrying out clinical trials of the drug to further characterise its bronchodilator and anti-inflammatory effects.
NR
Get the latest financial news, insights and expert analysis from our award-winning MoneyWeek team, to help you understand what really matters when it comes to your finances.
MoneyWeek is written by a team of experienced and award-winning journalists, plus expert columnists. As well as daily digital news and features, MoneyWeek also publishes a weekly magazine, covering investing and personal finance. From share tips, pensions, gold to practical investment tips - we provide a round-up to help you make money and keep it.
-
Two thirds of easy access savings accounts come with restrictions – can you access your savings in an emergency?
Out of the top 30 easy access savings on the market, 22 come with some sort of restriction on how fast you can access your money, according to new research.
-
Most popular London boroughs: Full list of in-demand places to move to
A deluge of people move to or within Britain’s capital each year – but which area is the most popular? We look at the most in-demand London boroughs in 2025.